|Celase GMP||1||35 mg||1235-01|
Celase GMP is a proprietary, blended proteolytic enzyme designed for efficient, gentle and reproducible in vitro dissociation of nucleated cells from adipose tissue.
- Now available as a standalone product
- Foundational and versatile for all research programs
- Eliminates time consuming, costly bridging studies
- Pack Size: 1 vial, 35 mg
- Samples: limited quantities available upon request
LABELING AND SPECIFICATIONS
TISSUE DISSOCIATION PROTOCOLS
- White Paper: Cytori Celase or SERVA Collagenase NB?
|Celbrush 3 mL||1||3 mL||503/CRS|
|Celbrush 3 mL Starter Kit||1||3 mL Kit||521/CRS|
|Celbrush 10 mL||1||10 mL||510/CRS|
|Celbrush 10 mL Starter Kit||1||10 mL Kit||520/CRS|
Celbrush is a stainless steel surgical instrument for precise delivery of micro droplets. The thumb-brush design gives the Celbrush a mechanical advantage that minimizes the build-up of pressure, and provides superior tactile feedback during tissue dispersion. This allows the surgeon, with a simple brush of his or her thumb, to exactly control the micro droplet tissue volume injected into the defect area without ever looking at the syringe, while simultaneously avoiding transient syringe obstruction and over-filling of the defect space.
For each full brush of the operator’s thumb, the Celbrush 3 mL and Celbrush 10 mL instruments deliver approximately 0.15 mL and 0.50 mL of tissue, respectively.
LABELING AND SPECIFICATIONS
Managed Access Programs provide biopharmaceutical companies with a way to allow compliant and ethical access to their pre-license/unlicensed medicines to help patients with unmet medical needs. Access is provided in response to physician requests when no alternative treatment options are available. The source of medicine funding varies by country and may be derived from the government, hospital, insurer, and/or patient.
The name ‘Managed Access Program’ is analogous to other terms often used for similar programs such as: named patient, special access, expanded access, early access, early use, compassionate use, single patient IND, treatment IND, special therapeutic, and cohort supply. The names used vary by company, country, program, and regulatory area.
Cytori’s Managed Access Program in select countries across Europe, the Middle East, and Africa is intended to provide patients with hand impairment due to scleroderma early access to ECCS-50 therapy. These patients typically are unable to participate in ongoing clinical trials due to a lack of geographic proximity to a trial site.
Companies such as Cytori which are authorized to distribute unlicensed medicines via a Managed Access Program are not involved in the patient-doctor relationship. All information regarding patients is controlled under specific privacy and data protection legislation. Cytori can only distribute where permitted to do so and only in response to an unsolicited information or product supply request.
Cytori’s Managed Access Program distributor is Idis Limited:
Tel: +44 (0)1932 824 169
Fax: +44 (0)1932 824 369
Please note: This contact information is intended for healthcare professionals only.